The company reported a net loss of $8.8 million for FY 2026, with no revenue and rising R&D and administrative expenses. Clinical progress was made with AL001, but additional capital is needed to fund ongoing trials and operations, and there is substantial doubt about the company's ability to conti…
The company reported a net loss of $8.8 million for FY 2026, with no revenue and rising R&D and administrative expenses. Clinical progress was made with AL001, but additional capital is needed to fund ongoing trials and operations, and there is substantial doubt about the company's ability to continue as a going concern.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
